The slimming consumer effect

Executive summary

GLP-1s are not just a new drug class; they represent the consumerisation of prescription therapeutics. Consumers are increasingly self-selecting into care pathways outside traditional healthcare infrastructure, which means brand choice and loyalty are often formed before a prescription is written. This shift is already rewiring spending behaviour across food, grocery, apparel, health, beauty and fitness. For leadership teams, the core question is no longer whether this will change the market, but who will capture value as it does. Organisations that delay risk finding themselves structurally downstream of decisions already made.

GLP-1s are not a drug category: they are a consumer movement

The clinical efficacy of GLP-1 receptor agonists matters, but it is not the disruption. 

Semaglutide, tirzepatide and the pipeline behind them are rightly judged on weight-loss outcomes and cardiovascular benefit. That clinical significance matters enormously; but the clinical story is not the disruption. The disruption is what is happening in parallel: a consumer-led explosion in demand that is bypassing traditional care pathways. 

Patients are not waiting for a GP referral. They are accessing testing and diagnostics in high-street pharmacies alongside everyday retail, subscribing to digital health platforms, ordering from online pharmacies, and making informed decisions based on available data, often acting faster than referral-based models allow. 

This is not patient non-compliance. This is the consumerisation of prescription therapeutics — and it changes everything downstream.

The Viagra moment revisited

The transition of Viagra from prescription-only to over-the-counter access demonstrated that well-understood safety profiles can support wider access, pharmacists can safely intermediate care, and stigma and friction dissolve when access improves. 

Those same conditions may increasingly apply to GLP-1s where today’s digital layer enables continuous monitoring, data capture, decision support and safety monitoring at scale.

Platforms such as Hims, Ro, Numan and Voy Second Nature are not simply dispensing medicines; they are wrapping clinical decision-support, continuous monitoring and personalised insight around the therapeutic in ways that in some cases rival traditional clinical interactions. As a result, regulators are observing a market that is functionally moving ahead of formal reclassification. 

What this means for pharma commercial teams

The traditional asset-centric commercial model, built around the molecule, the sales force and price defence, is under structural pressure. GLP-1 consumerisation accelerates its obsolescence.

When patients arrive informed, self-tested and with preferences already formed, the molecule alone is no longer the differentiator. Brand relationships increasingly begin before the prescription is written; and the commercial battleground shifts upstream to the digital platforms where patients research, the pharmacies where they prescribe, and the subscription services where they monitor. Forward looking pre-designed FMCG-style consumer insight becomes a core capability rather than an adjacent one. 

This requires a fundamental rethink of what the "product" actually is. The molecule is table stakes. The experience around it, the brand, the onboarding, the monitoring, the insight, the community, this is the commercial differentiator. Decisions leadership teams need to consider now include which consumer cohorts matter most and how they behave, where to partner versus build, and which data assets are strategically defensible. The next wave of launches — from Pfizer, Roche, Boehringer-Ingelheim and others - will enter a market that looks nothing like the one their commercial playbooks were written for.

Now, next, later

What this means for consumer health, FMCG and retail

The opportunity extends far beyond pharma.

GLP-1 users, predominantly women, are among the most engaged and intentional health consumers in the market. They are actively monitoring metabolic health, making nutrition and activity choices, and reallocating spend across categories.

Observed behavioural shifts include changes in food and grocery shopping toward reduced consumption and more nutrient-dense options with health being a key consideration in more consumption occasions; changes in apparel purchasing as consumers resize wardrobes or delay purchases during weight-loss phases; a shift in health and beauty spending toward supplements and functional products; and rising participation in fitness and exercise-related categories.

Taken together, GLP-1s are not only suppressing appetite, they are rewiring consumption behaviours, reallocating spend, and accelerating the shift toward intentional, health-led consumption, forcing consumer-facing categories across the board to rethink their portfolios. In categories like alcoholic beverages, carbonated soft drinks and confectionary, where more health and wellness orientated consumers have already been impacting volumes and investor confidence, this places even greater emphasis on strengthening consumer insight and innovation capabilities.

The strategic question is no longer how to sell to GLP-1 users, but how to become part of the GLP-1 journey.

Data as the competitive fault line

Retrospective data explains the past. In a consumerised market, advantage comes from prospective, real-time data captured through digital journeys.

This is not a nice to have. This data increasingly underpins personalised consumer experiences and retention, regulatory dialogue and evidence generation, and portfolio strategy and innovation prioritisation. Organisations that are not building these capabilities now (through partnerships with digital health platforms, online pharmacies and wearable ecosystems) are accumulating capability debt that will be expensive to close.

The Baringa perspective

Baringa operates at the intersection of pharmaceutical, consumer and retail, and technology expertise, bringing these perspectives together rather than treating them as separate disciplines. The challenge GLP-1-driven consumerisation presents is not a pharmaceutical problem, a consumer problem, or a technology problem in isolation. It is all three simultaneously, and the organisations that will lead are those able to connect them end-to-end, designing solutions that are clinically relevant, commercially compelling and digitally enabled.

For leadership teams, the next step is not another pilot. It is a strategic choice about where to play in a consumer-led health economy, which capabilities must be built or accessed now, and which partnerships are required before the window closes.

These are not easy questions. But they are, finally, the right ones.